{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 24 of 129', '3) The informed consent form must be signed prior to performing any protocol-related procedures, including but not limited to screening evaluations and washout of disallowed', 'medications.', '4)', \"Re-randomisation at Week 16: the treatment during the continuation treatment period will depend on the regimen received in the initial treatment period and on the subject's\", 'clinical response at Week 16 (see Section 7.1). Subjects will continue their use of TCS.', '5)', 'All', 'subjects', 'must use an emollient twice daily (or more, as needed) for at least 14 days before randomisation and must continue this treatment throughout the trial (including', 'safety follow-up).', '6)', 'For the first 3 IMP dosing visits (visits 3 to 5) and after re-randomisation (visits 11 to 13), subjects will be monitored after IMP administration for immediate drug reactions for a', 'minimum of 30 minutes with vital signs taken at 30 minutes or until stable, whichever is later (see Section 9.1.3.1).', '7)', 'eDiary includes: Eczema-related Sleep NRS, Worst Daily Pruritus NRS, Average Daily Pruritus NRS, Patient Days of Topical Treatment Use, PGI-B, and PGI-S; subjects will', 'complete daily from Week -2 to 32, except for Patient Days of Topical Treatment Use which will be completed daily from Week 0 to 32.', '8) IgE not assessed at screening.', 'Abbreviations: BSA, body surface area; C-SSRS, Columbia-Suicide Severity Rating Scale; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index;', 'EASI75, at least 75% reduction in EASI score; ECG, electrocardiogram; eDiary electronic diary; EQ-5D-5L, EuroQoL 5 Dimension Health Questionnaire 5 Level; HADS, Hospital', \"Anxiety and Depression Scale; IGA, Investigator's Global Assessment; IgE, immunoglobulin E; IMP, investigational medicinal product; NA, not applicable; NIMP, non-\", 'investigational medicinal product; NRS, numeric rating scale; PGI-B, Patient Global Impression of Bother; PGI-S, Patient Global Impression of Severity; POEM, Patient Oriented', 'Eczema Measure; SCORAD, Scoring Atopic Dermatitis; TCS, topical corticosteroid.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 25 of 129', 'Panel 3 Schedule of trial procedures: follow-up including early termination', 'SFU\u00b9', 'Nominal', '(end of trial)', 'Week 16 visit2', 'Early', 'Unscheduled', '(if applicable)', 'termination\u00b3', 'visit4 (if', 'Details', 'Visit', '20', '11x', '(if applicable)', 'applicable)', '(protocol section)', 'Week', '46', '16', 'Visit window (days)', '+3', '+3', 'Trial products', 'Concomitant medication/procedures', 'X', 'X', 'X', 'X4', '9.4,9.5', 'IMP administration, compliance', 'TCS (NIMP) dispensing', 'X4', '9.1.2,9.1.3.2', 'TCS (NIMP) return', 'X', 'X4', '9.8.3.2,9.8.5', 'Investigators global assessment of efficacy', 'IGA, EASI', 'X', 'X', 'X4', '10.3.1.1, 10.3.1.2', 'SCORAD', 'X', 'X', 'X4', '10.3.1.3', 'Atopic dermatitis flares', 'X', 'X4', '10.3.1.4', 'Subjects assessment of efficacy', 'eDiary3 completion', 'X', 'X', 'X4', '10.3.2', 'POEM', 'X', 'X', 'X4', '10.3.2.7', 'DLQI', 'X', 'X', 'X4', '10.3.2.8', 'EQ-5D-5L, HADS', 'X', 'X4', '10.3.2.9, 10.3.2.10', 'Safety assessments', 'Vital signs', 'X', 'X', 'X4', '10.4.1', 'Physical examination', 'X', 'X', 'X4', '10.4.2', 'EGGs', 'X', 'X', 'X4', '10.4.3', 'Urine pregnancy test', 'X', 'X', 'X4', '10.4.4', 'Serum chemistry, haematology, IgE', 'X', 'X', 'X4', '10.4.5', 'Urinalysis', 'X', 'X', 'X4', '10.4.5', 'Pharmacokinetics', 'X', 'X', 'X4', '10.4.6', 'Anti-drug antibodies', 'X', 'X', 'X4', '10.4.7', 'Adverse events', 'X', 'X', 'X', 'X4', '11, Appendix 1,', 'Appendix 2', '1) Subjects will have a final safety follow-up visit 16 weeks after the last dose of IMP (which is also considered end of trial', 'visit), except subjects who enter the long-term extension trial (conducted under a separate protocol [LP0162-1337,', 'ECZTEND]) for whom the end of trial visit will be the last visit in the present trial before transfer to ECZTEND.', '2)', 'Subjects who permanently discontinue IMP prior to Week 16 will also attend the nominal Week 16 visit (visit 11x).', '3)', 'Assessments and procedures performed at Week 16 (see Panel 2) are also to be done at an early termination visit.', '4)', \"Assessments and procedures to be performed at an unscheduled visit are left at the investigator's discretion; except if\", 'due to atopic dermatitis flares, then as a minimum IGA, EASI, concomitant medications/procedures, and AEs are to be', 'assessed.', '5)', 'eDiary includes: Eczema-related Sleep NRS, Worst Daily Pruritus NRS, Average Daily Pruritus NRS, Days of Topical', 'Treatment Use, Patient Global Impression of Bother, and Patient Global Impression of Severity; subjects will complete', 'daily (Week -2 to 32). Subjects who permanently discontinue IMP prior to Week 16 will complete the eDiary daily until', 'the Nominal Week 16 visit.', 'Abbreviations: DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; ECG, electrocardiogram;', 'eDiary, electronic diary; EQ-5D : 5L, EuroQoL 5-Dimension Health Questionnaire 5 Level; HADS, Hospital Anxiety and', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}